Azathioprine with Allopurinol Is a Promising First‑Line Therapy for Infammatory Bowel Diseases

The Mission
Key Opinion Leaders
International
Advisory Board
Initiatives
Discuss a case
Journal Scan
Latest News
Education Hub
Gallery


- Nov 27, 2021
Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes
- Nov 26, 2021
Mimics of Inflammatory Bowel Disease in Clinical Practice


- Nov 25, 2021
Inflammatory bowel disease in Bahrain: single-center experience
- Nov 18, 2021
Epidemiology of Inflammatory Bowel Diseases in Nepal


- Nov 18, 2021
Antibiotics for induction and maintenance of remission in UC: systematic review and meta-analysis


- Nov 18, 2021
Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach


- Nov 16, 2021
Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn's


- Nov 14, 2021
Noninvasive Monitoring After Azathioprine Withdrawal in Patients with Inflammatory Bowel Disease


- Nov 12, 2021
Impact of diagnostic delay to the clinical presentation and associated factors in pediatric IBD


- Nov 10, 2021
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment
- Nov 9, 2021
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U